GlassScriptPhysician profile
Sana Ghalib
NPI 1023460441
$15,949.89
in general payments reported to CMS, 2019-2025
31 companies · $9,320 in 2025
The $9,320 reported for 2025 was more than what 92% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $440 · 2022: $1,574 · 2023: $2,597 · 2024: $2,018 · 2025: $9,320.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $7,000 · Food and Beverage: $6,481 · Travel and Lodging: $455.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $7,000.00 |
| Food and Beverage | $6,480.58 |
| Travel and Lodging | $455.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $7,780.75 | 2024-2025 | |
| Glaxosmithkline, LLC. | $2,304.83 | 2021-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Astrazeneca Pharmaceuticals LP | $1,080.55 | 2021-2025 | Fasenra, Airsupra, Breztri |
| Genzyme Corporation | $729.47 | 2022-2025 | |
| Grifols USA, LLC | $544.27 | 2022-2025 | Prolastin-C Liquid |
| Regeneron Healthcare Solutions, INC. | $375.48 | 2023-2025 | Dupixent |
| Genentech USA, INC. | $358.90 | 2022-2025 | Xolair |
| Pulmonx Corporation | $312.10 | 2022-2024 | Zephyr Endobronchial Valve, Chartis Catheter, Pulmonx Chartis Tablet Console |
| Mylan Specialty L.P. | $298.70 | 2022-2024 | Yupelri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $253.43 | 2022-2025 | Ofev |
| Actelion Pharmaceuticals US, INC. | $230.26 | 2023-2024 | Opsumit, Uptravi |
| United Therapeutics Corporation | $221.65 | 2022-2025 | Tyvaso, Tyvaso |
| Electromed, INC. | $218.38 | 2022-2023 | Smartvest |
| Viatris Specialty LLC | $137.77 | 2025 | Yupelri |
| Merck Sharp & Dohme LLC | $131.67 | 2024-2025 | Winrevair |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $127.80 | 2022-2025 | Tezspire |
| Novartis Pharmaceuticals Corporation | $120.57 | 2023-2024 | |
| Verona Pharma, INC. | $119.03 | 2025 | Ohtuvayre |
| Genentech, INC. | $112.20 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $95.26 | 2022-2023 | Glassia |
| Baxter Healthcare | $82.18 | 2023-2025 | Hillrom - Vest System Model 105 Home Care, Hillrom - Life 2000 Ventilation System |
| Axsome Therapeutics, INC. | $80.69 | 2022-2023 | Sunosi |
| Erbe USA INC | $50.00 | 2024 | Cryo2 |
| Astellas Pharma US INC | $44.99 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $30.64 | 2022 | |
| Inspire Medical Systems, INC. | $26.51 | 2023 | Inspire |
| Mallinckrodt Hospital Products INC. | $18.85 | 2023 | Acthar |
| Jazz Pharmaceuticals INC. | $17.03 | 2023 | |
| Abbvie INC. | $16.82 | 2023 | |
| Inogen, INC. | $16.29 | 2023 | Inogen One G5 Oxygen Concentrator - Bluetooth |
| Paratek Pharmaceuticals, INC. | $12.82 | 2023 | Nuzyra |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sana Ghalib listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.